Literature DB >> 22268817

A comparison of Rapydan® patch and Ametop® gel for venous cannulation.

N Ravishankar1, S C Elliot, Z Beardow, A Mallick.   

Abstract

Ametop(®) gel (4% tetracaine) is used to provide topical anaesthesia for venous cannulation. Rapydan(®) patch (7% lidocaine and 7% tetracaine) has been developed to provide topical anaesthesia by a different mechanism, that of heat assisted delivery. We compared the topical anaesthetic effect of these agents for venous cannulation. One hundred healthy adults undergoing day-case surgery were randomly assigned to receive either Rapydan (n = 50) or Ametop (n = 50) before venous cannulation. Pain on insertion was scored on a visual analogue scale between 0 and 100 (where 100 = unbearable pain). Median(IQR[range]) pain scores were not different between groups with 11 (5-20 [0-72]) for Rapydan and 10 (5-24 [0-95]) for Ametop (p = 0.63). Adequate topical anaesthesia was achieved in over 90% of patients in both groups. Rapydan produces topical anaesthesia comparable with Ametop for venous cannulation. Anaesthesia
© 2012 The Association of Anaesthetists of Great Britain and Ireland.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22268817     DOI: 10.1111/j.1365-2044.2011.07000.x

Source DB:  PubMed          Journal:  Anaesthesia        ISSN: 0003-2409            Impact factor:   6.955


  2 in total

1.  Comparative Evaluation of Volatile Anaesthetic Agents for Attenuation of Venous Cannulation Pain: A Prospective, Randomized Controlled Study.

Authors:  Vinit K Srivastava; Pravin K Das; Sujeet Ks Gautam; Parineeta Jaisawal; Venkat N Kadiyala; Sonal Rambhad
Journal:  J Clin Diagn Res       Date:  2016-09-01

Review 2.  First do no harm: pain relief for the peripheral venous cannulation of adults, a systematic review and network meta-analysis.

Authors:  Mary Bond; Louise Crathorne; Jaime Peters; Helen Coelho; Marcela Haasova; Chris Cooper; Quentin Milner; Vicki Shawyer; Christopher Hyde; Roy Powell
Journal:  BMC Anesthesiol       Date:  2016-10-01       Impact factor: 2.217

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.